Limited TCF7L2 expression in MS lesions.
Multiple sclerosis is the most frequent demyelinating disease in the human CNS characterized by inflammation, demyelination, relative axonal loss and gliosis. Remyelination occurs, but is frequently absent or restricted to a small remyelinated rim at the lesion border. Impaired differentiation of ol...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23977356/pdf/?tool=EBI |
id |
doaj-7f48f265fe544222a33556836fbfcc39 |
---|---|
record_format |
Article |
spelling |
doaj-7f48f265fe544222a33556836fbfcc392021-03-03T22:58:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0188e7282210.1371/journal.pone.0072822Limited TCF7L2 expression in MS lesions.Alexander LürbkeKarin HagemeierQiao-Ling CuiImke MetzWolfgang BrückJack AntelTanja KuhlmannMultiple sclerosis is the most frequent demyelinating disease in the human CNS characterized by inflammation, demyelination, relative axonal loss and gliosis. Remyelination occurs, but is frequently absent or restricted to a small remyelinated rim at the lesion border. Impaired differentiation of oligodendroglial precursor cells is one factor contributing to limited remyelination, especially in chronic MS. TCF7L2 is an oligodendroglial transcription factor regulating myelin gene expression during developmental myelination as well as remyelination. TCF7L2 binds to co-effectors such as β-catenin or histone deacetylases and thereby activates or inhibits the transcription of downstream genes involved in oligodendroglial differentiation. To determine whether TCF7L2 can be used as a marker for differentiating or myelinating oligodendrocytes, we analyzed the expression patterns of TCF7L2 during myelination and remyelination in human and murine CNS tissue samples. Here, we demonstrate that marked expression of TCF7L2 in oligodendrocytes is restricted to a well defined time period during developmental myelination in human and mouse CNS tissue samples. In demyelinating diseases, such as multiple sclerosis, TCF7L2 is reexpressed in oligodendrocytes in a subset of MS patients, but is also present in tissue samples from patients with non-demyelinating, inflammatory diseases. Furthermore, TCF7L2 expression was also detected in astrocytes. HDAC2, a potential binding partner of TCF7L2 that promotes oligodendroglial differentiation and myelination, is expressed in the majority of oligodendrocytes in controls and MS tissue samples. In summary, our data demonstrate that the expression of TCF7L2 in oligodendrocytes is limited to a certain differentiation stage; however the expression of TCF7L2 is neither restricted to the oligodendroglial lineage nor to (re-)myelinating conditions.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23977356/pdf/?tool=EBI |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alexander Lürbke Karin Hagemeier Qiao-Ling Cui Imke Metz Wolfgang Brück Jack Antel Tanja Kuhlmann |
spellingShingle |
Alexander Lürbke Karin Hagemeier Qiao-Ling Cui Imke Metz Wolfgang Brück Jack Antel Tanja Kuhlmann Limited TCF7L2 expression in MS lesions. PLoS ONE |
author_facet |
Alexander Lürbke Karin Hagemeier Qiao-Ling Cui Imke Metz Wolfgang Brück Jack Antel Tanja Kuhlmann |
author_sort |
Alexander Lürbke |
title |
Limited TCF7L2 expression in MS lesions. |
title_short |
Limited TCF7L2 expression in MS lesions. |
title_full |
Limited TCF7L2 expression in MS lesions. |
title_fullStr |
Limited TCF7L2 expression in MS lesions. |
title_full_unstemmed |
Limited TCF7L2 expression in MS lesions. |
title_sort |
limited tcf7l2 expression in ms lesions. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Multiple sclerosis is the most frequent demyelinating disease in the human CNS characterized by inflammation, demyelination, relative axonal loss and gliosis. Remyelination occurs, but is frequently absent or restricted to a small remyelinated rim at the lesion border. Impaired differentiation of oligodendroglial precursor cells is one factor contributing to limited remyelination, especially in chronic MS. TCF7L2 is an oligodendroglial transcription factor regulating myelin gene expression during developmental myelination as well as remyelination. TCF7L2 binds to co-effectors such as β-catenin or histone deacetylases and thereby activates or inhibits the transcription of downstream genes involved in oligodendroglial differentiation. To determine whether TCF7L2 can be used as a marker for differentiating or myelinating oligodendrocytes, we analyzed the expression patterns of TCF7L2 during myelination and remyelination in human and murine CNS tissue samples. Here, we demonstrate that marked expression of TCF7L2 in oligodendrocytes is restricted to a well defined time period during developmental myelination in human and mouse CNS tissue samples. In demyelinating diseases, such as multiple sclerosis, TCF7L2 is reexpressed in oligodendrocytes in a subset of MS patients, but is also present in tissue samples from patients with non-demyelinating, inflammatory diseases. Furthermore, TCF7L2 expression was also detected in astrocytes. HDAC2, a potential binding partner of TCF7L2 that promotes oligodendroglial differentiation and myelination, is expressed in the majority of oligodendrocytes in controls and MS tissue samples. In summary, our data demonstrate that the expression of TCF7L2 in oligodendrocytes is limited to a certain differentiation stage; however the expression of TCF7L2 is neither restricted to the oligodendroglial lineage nor to (re-)myelinating conditions. |
url |
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23977356/pdf/?tool=EBI |
work_keys_str_mv |
AT alexanderlurbke limitedtcf7l2expressioninmslesions AT karinhagemeier limitedtcf7l2expressioninmslesions AT qiaolingcui limitedtcf7l2expressioninmslesions AT imkemetz limitedtcf7l2expressioninmslesions AT wolfgangbruck limitedtcf7l2expressioninmslesions AT jackantel limitedtcf7l2expressioninmslesions AT tanjakuhlmann limitedtcf7l2expressioninmslesions |
_version_ |
1714812020024410112 |